Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

09-11-2020 | ACR 2020 | Conference coverage | Video

Tofacitinib shows promise for ankylosing spondylitis

Lead investigator Atul Deodhar outlines the results of a phase 3 trial investigating tofacitinib as treatment option for ankylosing spondylitis, and discusses how JAK inhibitors might impact the spondyloarthritis treatment landscape (5:36).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

10-11-2020 | ACR 2020 | Conference coverage | News

Phase 3 trial demonstrates benefits of tofacitinib in ankylosing spondylitis

11-11-2020 | ACR 2020 | Conference coverage | Video

The potential impact of tofacitinib on AS treatment

06-04-2018 | Spondyloarthropathies | Feature | Article

At a glance: Trials of tofacitinib in spondyloarthritis

21-02-2019 | Spondyloarthropathies | Feature | Article

Trials of JAK inhibitors in spondyloarthritis: A round-up
Image Credits